SGLT2 inhibitors significantly reduced the composite of HF hospitalization or cardiovascular death [HR: 0.79 (0.72–0.85); I2 = 0%; P < 0.00001] (Fig. 2A). This evidence concerns the gene SLC5A2 and hydrops fetalis.